| Company Name: |
Energy Chemical |
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
N-Salicyloyltryptamine manufacturers
|
| | N-Salicyloyltryptamine Basic information |
| Product Name: | N-Salicyloyltryptamine | | Synonyms: | 2-Hydroxy-N-[2-(1H-indol-3-yl)ethyl]benzamide, STP;Benzamide, 2-hydroxy-N-[2-(1H-indol-3-yl)ethyl]-;N-Salicyloyltryptamine >=98% (HPLC), solid | | CAS: | 31384-98-2 | | MF: | C17H16N2O2 | | MW: | 280.32 | | EINECS: | | | Product Categories: | | | Mol File: | 31384-98-2.mol |  |
| | N-Salicyloyltryptamine Chemical Properties |
| Melting point | 153 °C(Solv: chloroform (67-66-3); methanol (67-56-1)) | | Boiling point | 578.1±40.0 °C(Predicted) | | density | 1.286±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: ~26 mg/mL | | form | solid | | pka | 8.52±0.30(Predicted) | | color | white |
| | N-Salicyloyltryptamine Usage And Synthesis |
| Uses | N-Salicyloyltryptamine acts on voltage-dependent Na+, Ca2+, and K+ ion channels inhibitor. N-Salicyloyltryptamine inhibits K+ currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect[1]-[5]. | | in vivo | N-Salicyloyltryptamine (100 mg/kg; i.p.; 60 min before stimulation challenge) significantly inhibits pentylenetetrazol (PTZ)-induced seizures and partially eliminates the extensor reflex of maximal electric-induced seizures test[4].
N-Salicyloyltryptamine (100 mg/kg, 200 mg/kg; i.p.; single dose) shows antinociceptive and nerve excitability effects[5].
| Animal Model: | Male Swiss mice (25-35 g)[4] | | Dosage: | 50, 100, 200 mg/kg | | Administration: | Intraperitoneal injection; single dose; 60 min before stimulation challenge | | Result: | Reduced the incidence of clonic pentylenetetrazol (PTZ) seizures and mortality at 50 mg/kg, and decreased the incidence of tonic hindlimb extension (THE) produced by MES at 100, 200 mg/kg.
|
| Animal Model: | Male Swiss mice (25-35 g)[5] | | Dosage: | 100 mg/kg; 200 mg/kg | | Administration: | Intraperitoneal injection; single dose | | Result: | Reduced the acetic acid-induced licking response of the injected paw.
|
| | IC 50 | L-type calcium channel; potassium channel: 34.6 μM (IC50) | | References | [1] Gasparotto J, et al Effect of N-salicyloyltryptamine (STP), a novel tryptamine analogue, on parameters of cell viability, oxidative stress, and immunomodulation in RAW 264.7 macrophages. Cell Biol Toxicol. 2013 Jun;29(3):175-87. DOI:10.1007/s10565-013-9245-2
[2] Araújo DA, et al. N-salicyloyltryptamine, a new anticonvulsant drug, acts on voltage-dependent Na+, Ca2+, and K+ ion channels. Br J Pharmacol. 2003 Dec;140(7):1331-9. DOI:10.1038/sj.bjp.0705471
[3] Veras RC, et al. N-Salicyloyltryptamine, an N-Benzoyltryptamine Analogue, Induces Vasorelaxation through Activation of the NO/sGC Pathway and Reduction of Calcium Influx. Molecules. 2018 Jan 28;23(2):253. DOI:10.3390/molecules23020253
[4] Oliveira FA, et al. Anticonvulsant properties of N-salicyloyltryptamine in mice. Pharmacol Biochem Behav. 2001 Feb;68(2):199-202. DOI:10.1016/s0091-3057(00)00484-6
[5] Quintans LJ Jr, et al. Bioassay-guided evaluation of antinociceptive effect of N-salicyloyltryptamine: a behavioral and electrophysiological approach. J Biomed Biotechnol. 2010;2010:230745. DOI:10.1155/2010/230745 |
| | N-Salicyloyltryptamine Preparation Products And Raw materials |
|